ストックスクリーナーアプリを入手
1.59
7.43%
0.11
前日終値:
$1.48
開ける：
$1.5
24時間の取引高:
1.48M
Relative Volume:
1.60
時価総額：
$114.70M
収益：
-
当期純損益:
$-292.19M
株価収益率:
-0.3502
EPS:
-4.54
ネットキャッシュフロー:
$-208.41M
1週間 パフォーマンス:
+10.42%
1か月 パフォーマンス:
+18.66%
6か月 パフォーマンス:
-34.57%
1年 パフォーマンス:
-50.31%
1日の値動き範囲:
$1.50
$1.6994
1週間の範囲:
$1.36
$1.6994
52週間の値動き範囲:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.59 | 106.76M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-12 | アップグレード | Wedbush | Underperform → Neutral |
| 2024-06-20 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-06-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | ダウングレード | Wedbush | Neutral → Underperform |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Zentalis Pharmaceuticals Inc. stock outlook for YEARPortfolio Update Summary & Target Return Focused Stock Picks - Newser
Custom watchlist performance reports with Zentalis Pharmaceuticals Inc.July 2025 Selloffs & Safe Entry Point Identification - Newser
Analyzing recovery setups for Zentalis Pharmaceuticals Inc. investorsWeekly Stock Analysis & Community Verified Trade Signals - Newser
Can a trend reversal in Zentalis Pharmaceuticals Inc. lead to recovery2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
How to integrate Zentalis Pharmaceuticals Inc. into portfolio analysis toolsTrade Risk Report & Daily Profit Maximizing Tips - Newser
Published on: 2025-08-15 04:37:23 - Newser
What are the risks of holding Zentalis Pharmaceuticals Inc.Profit Target & Consistent Income Trade Recommendations - kangso.co.kr
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.July 2025 News Drivers & Proven Capital Preservation Tips - Newser
Using economic indicators to assess Zentalis Pharmaceuticals Inc. potentialWeekly Investment Report & Fast Momentum Entry Tips - Newser
Price Clustering Detected in Zentalis Pharmaceuticals Inc. StockMarket Risk Analysis & Fast Entry Momentum Alerts - 선데이타임즈
Using flow based indicators on Zentalis Pharmaceuticals Inc.July 2025 Outlook & Daily Growth Stock Investment Tips - Newser
Has Zentalis Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewTrend Reversal Watch with Entry Signals - Newser
Applying Wyckoff theory to Zentalis Pharmaceuticals Inc. stockHigh Win Rate Strategy with Stop Protection - Newser
Is Zentalis Pharmaceuticals Inc. stock a smart retirement pickROI Focused Stock Opportunities - mustnews.co.kr
Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - MarketBeat
Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings - Defense World
Equities Analysts Offer Predictions for ZNTL Q3 Earnings - Defense World
When is the best time to exit Zentalis Pharmaceuticals Inc.Predictive AI Signals for Short-Term Trading - Newser
Watch for Trend Continuation in Zentalis Pharmaceuticals Inc. Next WeekTechnical Stock Breakout Predictions Signal Entry Points - beatles.ru
Zentalis price target lowered to $5 from $6 at Wells Fargo - MSN
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionFree Trend Analysis for Safer Trades - Newser
ZNTL: Wells Fargo Adjusts Price Target, Maintains Rating | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism - TipRanks
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals - TipRanks
Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - 富途牛牛
Zentalis Pharmaceuticals Reports Improved Financial Results - TipRanks
Zentalis (ZNTL) Q2 Loss Narrows 70% - The Motley Fool
Zentalis (ZNTL) Q2 Loss Narrows 70% - AOL.com
Zentalis Pharmaceuticals: Navigating the Crossroads of Innovation and Financial Prudence - AInvest
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Zentalis Pharma's Q2 operating expenses down - TradingView
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewswire
Zentalis Advances Revolutionary Ovarian Cancer Drug with $303M War Chest, FDA Fast-Track Potential - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
Zentalis Pharmaceuticals Inc (ZNTL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):